<DOC>
	<DOCNO>NCT02724852</DOCNO>
	<brief_summary>This prevalence study protective antibody measles , mumps , rubella ( MMR ) HIV-infected adults HIV-uninfected control . MMR vaccination provide group protective antibody least one three virus .</brief_summary>
	<brief_title>MMR Vaccination Among HIV-infected Adults</brief_title>
	<detailed_description>From July August 2011 , 500 HIV-infected 132 HIV-uninfected participant meet eligibility criterion enrol tested protective antibody measles , mumps , rubella . All participant protective antibody least one three virus recruit vaccinate MMR vaccine . Between June September 2012 , 249 HIV-infected 46 HIV-uninfected adult vaccinate . Antibodies MMR measure week 8-12 , week 48 vaccination , complete August 2013 . The result ready analysis March 2014 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For HIVinfected participant , inclusion criteria 1 . 2059 year old , ability provide inform consent 2. receive cART 3 . CD4 cell count ≥200 cell/mm3 within 6 month enrollment 4. plasma HIV1 RNA &lt; 50 copies/mL , 5 ) ability provide inform consent . For group 1. pregnancy lactate 2. receive cancer treatment , organ transplantation , ≥0.5 mg/kg/day prednisolone equivalent , immunomodulating treatment 3. impaired renal function ( creatinine clearance &lt; 30 mL/min ) 4. impaired liver function define ChildPugh C .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MMR</keyword>
	<keyword>vaccination</keyword>
	<keyword>HIV</keyword>
	<keyword>Serologic response</keyword>
</DOC>